

TABLE OF CONTENTS

Section		Page
	List of Figures	xiv
	List of Tables	xv
	Glossary and Abbreviations	xix
	Acknowledgments	xxv
	Executive Summary	xxviii
1	Introduction	1-1
	1.1 Overview and Objectives	1-1
	1.2 Contents of Volume 2	1-3
	1.3 Sources	1-7
2	Risk Assessment Methods	2-1
	2.1 Introduction	2-1
	2.1.1 Other Information Sources	2-3
	2.2 Hazard Identification	2-4
	2.2.1 Approach for Fish Contaminants	2-5
	2.2.1.1 Toxicological Data	2-5
	2.2.1.2 Contaminant Data	2-6
	2.2.1.3 Sources of Exposure	2-7
	2.2.2 Assumptions and Uncertainty Analysis	2-8
	2.3 Dose-Response Assessment	2-9
	2.3.1 Carcinogenic Effects	2-11
	2.3.2 Noncarcinogenic Effects	2-13
	2.3.2.1 Acute Exposure	2-13
	2.3.2.2 Systemic Effects from Chronic Exposure	2-14
	2.3.2.3 Developmental Toxicity	2-18
	2.3.3 Mutagenicity/Genotoxicity	2-28
	2.3.4 Multiple Chemical Exposures: Interactive Effects	2-28
	2.3.5 Assumptions and Uncertainties	2-30
	2.4 Exposure Assessment	2-33
	2.4.1 Chemical Occurrences in Fish	2-34
	2.4.2 Geographic Distribution of Contaminated Fish	2-35
	2.4.3 Individual Exposure Assessment	2-35
	2.4.3.1 Exposure Variables	2-36
	2.4.3.2 Averaging Periods Versus Exposure Durations	2-39
	2.4.3.3 Multiple Species Exposures	2-41
	2.4.3.4 Multiple Chemical Exposures	2-42

TABLE OF CONTENTS

Section	Page
2.4.4 Population Exposure Assessments	2-42
2.4.4.1 Categories of Population Exposure Assessment Information	2-42
2.4.4.2 Categorizing Exposure Levels	2-45
2.4.5 Uncertainty and Assumptions	2-48
2.4.5.1 Chemical Contaminant Concentrations in Fish	2-48
2.4.5.2 Dose Modifications Due to Food Preparation and Cooking	2-49
2.4.5.3 Body Weight	2-49
2.4.5.4 Consumption Rate and Averaging Period	2-49
2.4.5.5 Multiple Species and Multiple Contaminants	2-52
2.4.5.6 Other Sources of Exposure	2-53
2.5 Risk Characterization	2-58
2.5.1 Carcinogenic Toxicity	2-59
2.5.1.1 Individual Risk	2-60
2.5.1.2 Population Risk	2-60
2.5.2 Noncarcinogenic Toxicity	2-61
2.5.2.1 Individual Risk	2-61
2.5.2.2 Population Risk	2-61
2.5.3 Subpopulation Considerations	2-62
2.5.4 Multiple Species and Multiple Contaminant Considerations	2-64
2.5.5 Incorporating Considerations of Uncertainty in Consumption Limits	2-64
2.6 Summarizing Risk Data	2-65
3 Development and Use of Risk-Based Consumption Limits	3-1
3.1 Overview and Section Organization	3-1
3.2 Equations Used to Develop Risk-Based Consumption Limits	3-2
3.2.1 Calculation of Consumption Limits for Carcinogenic Effects	3-2
3.2.1.1 Calculation of Daily Consumption Limits	3-5
3.2.1.2 Calculation of Meal Consumption Limits	3-5
3.2.1.3 Input Parameters	3-6
3.2.2 Calculation of Consumption Limits for Noncarcinogenic Effects	3-6
3.2.2.1 Calculation of Daily Consumption Limits	3-9
3.2.2.2 Calculation of Meal Consumption Limits	3-11
3.2.2.3 Input Parameters	3-12
3.2.3 Calculation of Consumption Limits for Developmental Effects	3-12
3.3 Default and Alternative Values for Calculating Consumption Limits	3-15
3.3.1 Maximum Acceptable Risk Level	3-15

TABLE OF CONTENTS

Section	Page
3.3.2 Cancer Potencies and Chronic Reference Doses (q_1^* 's and RfDs)	3-18
3.3.3 Consumer Body Weight (BW)	3-20
3.3.3.1 Derivation of Multipliers for Body Weight Adjustment	3-21
3.3.4 Meal Size	3-23
3.3.5 Contaminant Concentration in Fish Tissue	3-28
3.3.6 Modifying Time-Averaging Period (T_{ap})	3-29
3.4 Modification of Consumption Limits for a Single Contaminant in a Multispecies Diet	3-31
3.4.1 Carcinogenic Effects	3-32
3.4.2 Noncarcinogenic Effects	3-33
3.5 Modification of Consumption Limits for Multiple Contaminant Exposures	3-35
3.5.1 Carcinogenic Effects	3-36
3.5.2 Noncarcinogenic Effects	3-37
3.5.3 Species-Specific Consumption Limits in a Multiple Species Diet	3-39
3.6 Choice of Consumption Limits	3-40
 4 Risk-Based Consumption Limit Tables	4-1
4.1 Overview and Section Organization	4-1
4.2 Consumption Limit Tables	4-4
 5 Toxicological Profile Summaries for Target Analytes	5-1
5.1 Introduction	5-1
5.1.1 Categories of Information Provided for Target Analytes	5-1
5.1.1.1 Pharmacokinetics	5-2
5.1.1.2 Acute Toxicity	5-4
5.1.1.3 Chronic Toxicity	5-4
5.1.1.4 Developmental Toxicity	5-4
5.1.1.5 Mutagenicity	5-5
5.1.1.6 Carcinogenicity	5-5
5.1.1.7 Special Susceptibilities	5-6
5.1.1.8 Interactive Effects	5-7
5.1.1.9 Critical Data Gaps	5-7
5.1.1.10 Summary of EPA Levels of Concern	5-7
5.1.1.11 Major Sources	5-7
5.1.1.12 Statement Regarding Uncertainty	5-8
5.1.2 Abbreviations Used and Scientific Notation	5-8
5.2 Metals	5-10
5.2.1 Arsenic	5-10
5.2.1.1 Background	5-10
5.2.1.2 Pharmacokinetics	5-10
5.2.1.3 Acute Toxicity	5-10
5.2.1.4 Chronic Toxicity	5-10

TABLE OF CONTENTS

Section		Page
	5.2.1.5 Developmental Toxicity	5-11
	5.2.1.6 Mutagenicity	5-12
	5.2.1.7 Carcinogenicity	5-12
	5.2.1.8 Special Susceptibilities	5-12
	5.2.1.9 Interactive Effects	5-13
	5.2.1.10 Critical Data Gaps	5-13
	5.2.1.11 Summary of EPA Levels of Concern	5-13
	5.2.1.12 Major Sources	5-13
5.2.2	Cadmium	5-13
	5.2.2.1 Background	5-13
	5.2.2.2 Pharmacokinetics	5-14
	5.2.2.3 Acute Toxicity	5-14
	5.2.2.4 Chronic Toxicity	5-15
	5.2.2.5 Developmental Toxicity	5-16
	5.2.2.6 Mutagenicity	5-17
	5.2.2.7 Carcinogenicity	5-17
	5.2.2.8 Special Susceptibilities	5-18
	5.2.2.9 Interactive Effects	5-18
	5.2.2.10 Critical Data Gaps	5-18
	5.2.2.11 Summary of EPA Levels of Concern	5-19
	5.2.2.12 Major Sources	5-19
5.2.3	Mercury	5-19
	5.2.3.1 Background	5-19
	5.2.3.2 Pharmacokinetics	5-20
	5.2.3.3 Acute Toxicity	5-20
	5.2.3.4 Chronic Toxicity	5-20
	5.2.3.5 Developmental Toxicity	5-24
	5.2.3.6 Mutagenicity	5-25
	5.2.3.7 Carcinogenicity	5-25
	5.2.3.8 Special Susceptibilities	5-25
	5.2.3.9 Interactive Effects	5-26
	5.2.3.10 Critical Data Gaps	5-26
	5.2.3.11 Summary of EPA Levels of Concern	5-26
	5.2.3.12 Major Sources	5-26
5.2.4	Selenium	5-26
	5.2.4.1 Background	5-26
	5.2.4.2 Pharmacokinetics	5-27
	5.2.4.3 Acute Toxicity	5-27
	5.2.4.4 Chronic Toxicity	5-27
	5.2.4.5 Developmental Toxicity	5-29
	5.2.4.6 Mutagenicity	5-31
	5.2.4.7 Carcinogenicity	5-31
	5.2.4.8 Special Susceptibilities	5-31
	5.2.4.9 Interactive Effects	5-32
	5.2.4.10 Critical Data Gaps	5-32
	5.2.4.11 Summary of EPA Levels of Concern	5-32

TABLE OF CONTENTS

Section		Page
	5.2.4.12 Major Sources	5-32
5.2.5	Tributyltin Oxide	5-32
	5.2.5.1 Background	5-32
	5.2.5.2 Pharmacokinetics	5-33
	5.2.5.3 Acute Toxicity	5-33
	5.2.5.4 Chronic Toxicity	5-33
	5.2.5.5 Developmental Toxicity	5-34
	5.2.5.6 Mutagenicity	5-34
	5.2.5.7 Carcinogenicity	5-34
	5.2.5.8 Special Susceptibilities	5-34
	5.2.5.9 Interactive Effects	5-35
	5.2.5.10 Critical Data Gaps	5-35
	5.2.5.11 Summary of EPA Levels of Concern	5-35
	5.2.5.12 Major Sources	5-35
5.3	Organochlorine Pesticides	5-36
5.3.1	Chlordane	5-36
	5.3.1.1 Background	5-36
	5.3.1.2 Pharmacokinetics	5-36
	5.3.1.3 Acute Toxicity	5-36
	5.3.1.4 Chronic Toxicity	5-37
	5.3.1.5 Developmental Toxicity	5-37
	5.3.1.6 Mutagenicity	5-38
	5.3.1.7 Carcinogenicity	5-38
	5.3.1.8 Special Susceptibilities	5-39
	5.3.1.9 Interactive Effects	5-39
	5.3.1.10 Critical Data Gaps	5-40
	5.3.1.11 Summary of EPA Levels of Concern	5-40
	5.3.1.12 Major Sources	5-40
5.3.2	DDT, DDE, DDD	5-40
	5.3.2.1 Background	5-40
	5.3.2.2 Pharmacokinetics	5-41
	5.3.2.3 Acute Toxicity	5-41
	5.3.2.4 Chronic Toxicity	5-41
	5.3.2.5 Developmental Toxicity	5-42
	5.3.2.6 Mutagenicity	5-44
	5.3.2.7 Carcinogenicity	5-44
	5.3.2.8 Special Susceptibilities	5-44
	5.3.2.9 Interactive Effects	5-45
	5.3.2.10 Critical Data Gaps	5-45
	5.3.2.11 Summary of EPA Levels of Concern	5-46
	5.3.2.12 Major Sources	5-46
5.3.3	Dicofol (Kelthane)	5-46
	5.3.3.1 Background	5-46
	5.3.3.2 Pharmacokinetics	5-46
	5.3.3.3 Acute Toxicity	5-46
	5.3.3.4 Chronic Toxicity	5-46

TABLE OF CONTENTS

Section		Page
	5.3.3.5 Developmental Toxicity	5-47
	5.3.3.6 Mutagenicity	5-47
	5.3.3.7 Carcinogenicity	5-48
	5.3.3.8 Special Susceptibilities	5-48
	5.3.3.9 Interactive Effects	5-48
	5.3.3.10 Critical Data Gaps	5-48
	5.3.3.11 Summary of EPA Levels of Concern	5-48
	5.3.3.12 Major Sources	5-48
5.3.4	Dieldrin	5-49
	5.3.4.1 Background	5-49
	5.3.4.2 Pharmacokinetics	5-49
	3.3.4.3 Acute Toxicity	5-49
	5.3.4.4 Chronic Toxicity	5-49
	5.3.4.5 Developmental Toxicity	5-51
	5.3.4.6 Mutagenicity	5-53
	5.3.4.7 Carcinogenicity	5-53
	5.3.4.8 Special Susceptibilities	5-54
	5.3.4.9 Interactive Effects	5-54
	5.3.4.10 Critical Data Gaps	5-54
	5.3.4.11 Summary of EPA Levels of Concern	5-54
	5.3.4.12 Major Sources	5-54
5.3.5	Endosulfan I, II	5-55
	5.3.5.1 Background	5-55
	5.3.5.2 Pharmacokinetics	5-55
	5.3.5.3 Acute Toxicity	5-55
	5.3.5.4 Chronic Toxicity	5-55
	5.3.5.5 Developmental Toxicity	5-56
	5.3.5.6 Mutagenicity	5-57
	5.3.5.7 Carcinogenicity	5-57
	5.3.5.8 Special Susceptibilities	5-58
	5.3.5.9 Interactive Effects	5-58
	5.3.5.10 Critical Data Gaps	5-58
	5.3.5.11 Summary of EPA Levels of Concern	5-59
	5.3.5.12 Major Sources	5-59
5.3.6	Endrin	5-59
	5.3.6.1 Background	5-59
	5.3.6.2 Pharmacokinetics	5-59
	5.3.6.3 Acute Toxicity	5-59
	5.3.6.4 Chronic Toxicity	5-59
	5.3.6.5 Developmental Toxicity	5-60
	5.3.6.6 Mutagenicity	5-61
	5.3.6.7 Carcinogenicity	5-61
	5.3.6.8 Special Susceptibilities	5-61
	5.3.6.9 Interactive Effects	5-61
	5.3.6.10 Critical Data Gaps	5-62
	5.3.6.11 Summary of EPA Levels of Concern	5-62

TABLE OF CONTENTS

Section		Page
	5.3.6.12 Major Sources	5-62
5.3.7	Heptachlor Epoxide	5-62
	5.3.7.1 Background	5-62
	5.3.7.2 Pharmacokinetics	5-62
	5.3.7.3 Acute Toxicity	5-63
	5.3.7.4 Chronic Toxicity	5-63
	5.3.7.5 Developmental Toxicity	5-63
	5.3.7.6 Mutagenicity	5-64
	5.3.7.7 Carcinogenicity	5-64
	5.3.7.8 Special Susceptibilities	5-65
	5.3.7.9 Interactive Effects	5-65
	5.3.7.10 Critical Data Gaps	5-65
	5.3.7.11 Summary of EPA Levels of Concern	5-65
	5.3.7.12 Major Sources	5-65
5.3.8	Hexachlorobenzene	5-65
	5.3.8.1 Background	5-65
	5.3.8.2 Pharmacokinetics	5-66
	5.3.8.3 Acute Exposure	5-66
	5.3.8.4 Chronic Toxicity	5-66
	5.3.8.5 Developmental Toxicity	5-67
	5.3.8.6 Mutagenicity	5-68
	5.3.8.7 Carcinogenicity	5-68
	5.3.8.8 Special Susceptibilities	5-68
	5.3.8.9 Interactive Effects	5-69
	5.3.8.10 Critical Data Gaps	5-69
	5.3.8.11 Summary of EPA Levels of Concern	5-69
	5.3.8.12 Major Sources	5-69
5.3.9	Lindane (γ -hexachlorocyclohexane)	5-69
	5.3.9.1 Background	5-69
	5.3.9.2 Pharmacokinetics	5-69
	5.3.9.3 Acute Toxicity	5-70
	5.3.9.4 Chronic Toxicity	5-70
	5.3.9.5 Developmental Toxicity	5-71
	5.3.9.6 Mutagenicity	5-72
	5.3.9.7 Carcinogenicity	5-72
	5.3.9.8 Special Susceptibilities	5-73
	5.3.9.9 Interactive Effects	5-73
	5.3.9.10 Critical Data Gaps	5-73
	5.3.9.11 Summary of EPA Levels of Concern	5-74
	5.3.9.12 Major Sources	5-74
5.3.10	Mirex	5-74
	5.3.10.1 Background	5-74
	5.3.10.2 Pharmacokinetics	5-74
	5.3.10.3 Acute Toxicity	5-75
	5.3.10.4 Chronic Toxicity	5-75
	5.3.10.5 Developmental Toxicity	5-76

TABLE OF CONTENTS

Section		Page
	5.3.10.6 Mutagenicity	5-77
	5.3.10.7 Carcinogenicity	5-77
	5.3.10.8 Special Susceptibilities	5-77
	5.3.10.9 Interactive Effects	5-78
	5.3.10.10 Critical Data Gaps	5-78
	5.3.10.11 Summary of EPA Levels of Concern	5-78
	5.3.10.12 Major Sources	5-78
5.3.11	Toxaphene	5-78
	5.3.11.1 Background	5-78
	5.3.11.2 Pharmacokinetics	5-78
	5.3.11.3 Acute Toxicity	5-79
	5.3.11.4 Chronic Toxicity	5-79
	5.3.11.5 Developmental Toxicity	5-79
	5.3.11.6 Mutagenicity	5-81
	5.3.11.7 Carcinogenicity	5-81
	5.3.11.8 Special Susceptibilities	5-81
	5.3.11.9 Interactive Effects	5-82
	5.3.11.10 Critical Data Gaps	5-83
	5.3.11.11 Summary of EPA Levels of Concern	5-83
	5.3.11.12 Major Sources	5-83
5.4	Organophosphate Pesticides	5-84
5.4.1	Chlorpyrifos	5-84
	5.4.1.1 Background	5-84
	5.4.1.2 Pharmacokinetics	5-84
	5.4.1.3 Acute Toxicity	5-84
	5.4.1.4 Chronic Toxicity	5-84
	5.4.1.5 Developmental Toxicity	5-85
	5.4.1.6 Mutagenicity	5-85
	5.4.1.7 Carcinogenicity	5-86
	5.4.1.8 Special Susceptibilities	5-86
	5.4.1.9 Interactive Effects	5-86
	5.4.1.10 Critical Data Gaps	5-86
	5.4.1.11 Summary of Levels of Concern	5-86
	5.4.1.12 Major Sources	5-86
5.4.2	Diazinon	5-86
	5.4.2.1 Background	5-86
	5.4.2.2 Pharmacokinetics	5-86
	5.4.2.3 Acute Toxicity	5-87
	5.4.2.4 Chronic Toxicity	5-87
	5.4.2.5 Developmental Toxicity	5-87
	5.4.2.6 Mutagenicity	5-88
	5.4.2.7 Carcinogenicity	5-88
	5.4.2.8 Special Susceptibilities	5-88
	5.4.2.9 Interactive Effects	5-88
	5.4.2.10 Critical Data Gaps	5-88
	5.4.2.11 Summary of EPA Levels of Concern	5-88

TABLE OF CONTENTS

Section		Page
	5.4.2.12 Major Sources	5-88
5.4.3	Disulfoton (disyston)	5-88
	5.4.3.1 Background	5-88
	5.4.3.2 Pharmacokinetics	5-89
	5.4.3.3 Acute Toxicity	5-89
	5.4.3.4 Chronic Toxicity	5-89
	5.4.3.5 Developmental Toxicity	5-89
	5.4.3.6 Mutagenicity	5-90
	5.4.3.7 Carcinogenicity	5-90
	5.4.3.8 Special Susceptibilities	5-90
	5.4.3.9 Interactive Effects	5-91
	5.4.3.10 Critical Data Gaps	5-91
	5.4.3.11 Summary of EPA Levels of Concern	5-91
	5.4.3.12 Major Sources	5-91
5.4.4	Ethion	5-91
	5.4.4.1 Background	5-91
	5.4.4.2 Pharmacokinetics	5-91
	5.4.4.3 Acute Toxicity	5-91
	5.4.4.4 Chronic Toxicity	5-91
	5.4.4.5 Developmental Toxicity	5-92
	5.4.4.6 Mutagenicity	5-92
	5.4.4.7 Carcinogenicity	5-92
	5.4.4.8 Special Susceptibilities	5-92
	5.4.4.9 Interactive Effects	5-92
	5.4.4.10 Critical Data Gaps	5-93
	5.4.4.11 Summary of EPA Levels of Concern	5-93
	5.4.4.12 Major Sources	5-93
5.4.5	Terbufos	5-93
	5.4.5.1 Background	5-93
	5.4.5.2 Pharmacokinetics	5-93
	5.4.5.3 Acute Toxicity	5-93
	5.4.5.4 Chronic Toxicity	5-93
	5.4.5.5 Developmental Toxicity	5-94
	5.4.5.6 Mutagenicity	5-95
	5.4.5.7 Carcinogenicity	5-95
	5.4.5.8 Special Susceptibilities	5-95
	5.4.5.9 Interactive Effects	5-95
	5.4.5.10 Critical Data Gaps	5-95
	5.4.5.11 Summary of EPA Levels of Concern	5-96
	5.4.5.12 Major Sources	5-96
5.5	Chlorophenoxy Herbicides	5-97
5.5.1	Oxyfluorfen	5-97
	5.5.1.1 Background	5-97
	5.5.1.2 Pharmacokinetics	5-97
	5.5.1.3 Acute Toxicity	5-97
	5.5.1.4 Chronic Toxicity	5-97

TABLE OF CONTENTS

Section	Page
5.5.1.5 Developmental Toxicity	5-97
5.5.1.6 Mutagenicity	5-97
5.5.1.7 Carcinogenicity	5-98
5.5.1.8 Interactive Effects	5-98
5.5.1.9 Critical Data Gaps	5-98
5.5.10 Summary of EPA Levels of Concern	5-98
5.5.1.11 Major Sources	5-98
5.6 Polycyclic Aromatic Hydrocarbons (PAHs)	5-99
5.6.1 Background	5-99
5.6.2 Pharmacokinetics	5-99
5.6.3 Acute Toxicity	5-100
5.6.4 Chronic Toxicity	5-100
5.6.5 Developmental Toxicity	5-100
5.6.6 Mutagenicity	5-100
5.6.7 Carcinogenicity	5-101
5.6.8 Special Susceptibilities	5-102
5.6.9 Interactive Effects	5-103
5.6.10 Critical Data Gaps	5-104
5.6.11 Summary of EPA Levels of Concern	5-104
5.6.12 Major Sources	5-104
5.7 Polychlorinated Biphenyls (PCBs)	5-105
5.7.1 Background	5-105
5.7.2 Pharmacokinetics	5-105
5.7.3 Acute Toxicity	5-106
5.7.4 Chronic Toxicity	5-107
5.7.5 Developmental Toxicity	5-107
5.7.6 Mutagenicity	5-111
5.7.7 Carcinogenicity	5-111
5.7.8 Special Susceptibilities	5-112
5.7.9 Interactive Effects	5-113
5.7.10 Critical Data Gaps	5-113
5.7.11 Summary of EPA Levels of Concern	5-113
5.7.12 Major Sources	5-113
5.8 Dioxins	5-114
5.8.1 Background	5-114
5.8.2 Summary of EPA Levels of Concern	5-114
5.8.3 Major Source	5-114
6 Mapping Tools for Risk Assessment and Risk Management	6-1
6.1 Overview of Population and Contaminant Mapping	6-1
6.2 Objectives of Mapping	6-1
6.3 Basic GIS Concepts for Population and Contaminant Mapping	6-2
6.4 Internet Sources of Existing Data Files and GIS Coverages	6-5
6.5 Data Needed for Mapping	6-6
6.6 Mapping Programs	6-8

TABLE OF CONTENTS

Section		Page
7	Literature Cited	7-1
Appendix		
A	Sources of Additional Information	A-1
B	Mutagenicity and Genotoxicity Guidelines	B-1
C	Toxicity Characteristics of Groups of Analytes	C-1
D	Population Exposure Assessment—Consumption Patterns and Surveys	D-1
E	Dose Modification Due to Food Preparation and Cooking	E-1
F	Guidance for Risk Characterization	F-1
G	Sample Consumption Limit Tables	G-1
H	Summary of Limits of Detection for the Recommended Target Analytes	H-1

LIST OF FIGURES

Number		Page
1-1	Series Summary: Guidance for Assessing Chemical Contamination Data for Use in Fish Advisories	1-5
2-1	Elements of Risk Assessment and Risk Management	2-2
2-2	Schematic of Exposure Categories in Upper Half of a Normal Population Distribution	2-46
3-1	Current RfD for Methylmercury with Associated Range of Uncertainty and Corresponding Fish Tissue Contamination Levels	3-10
6-1	GIS Data Layers May Use Raster or Vector Representation Techniques	6-3
6-2	Examples of GIS Displays from EPA's BASINInfo Maps-on-Demand Facility	6-7
6-3	Map Showing Active Fish and Wildlife Advisories for a State	6-7

LIST OF TABLES

Number		Page
1-1	Target Analytes Recommended for Fish Sampling Programs	1-4
2-1	Uncertainty Factors and Modifying Factors for Estimating Exposure Limits for Developmental Effects	2-16
2-2	Mean Body Weights of Children and Adults	2-37
2-3	Categories of Information Necessary for a Population Exposure Assessment	2-43
2-4	Exposure Data Template	2-56
2-5	Risk Estimates	2-66
2-6	Risk Characterization	2-67
2-7	Risk Summaries for a Waterbody	2-68
2-8	Risk Summaries for a Geographic Area	2-70
3-1	Risk Values Used in Risk-Based Consumption Limit Tables	3-3
3-2	Input Parameters for Use in Risk Equations	3-7
3-3	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Chlordane	3-8
3-4	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Chlordane	3-13
3-5	Monthly Consumption Limits for Developmental Health Endpoints for Women of Reproductive Age—PCBs (Aroclor 1016)	3-16
3-6	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—PCBs (Aroclor 1254)	3-17
3-7	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Chlordane	3-19
3-8	Average Body Weights and Associated Multipliers	3-21
3-9	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Chlordane	3-24
3-10	Alternative Meal Sizes and Associated Multipliers	3-25
3-11	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Chlordane	3-27
3-12	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Chlordane	3-29
3-13	10-Day Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Chlordane	3-32

LIST OF TABLES

Number		Page
4-1	Index to Monthly Consumption Limit Tables for Target Analytes	4-5
4-2	Summary of RfD, CSF, and Detection Limit Values Used to Develop Fish Consumption Limits	4-6
4-3	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Arsenic (inorganic)	4-7
4-4	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Arsenic (inorganic)	4-8
4-5	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Arsenic (inorganic)	4-9
4-6	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Cadmium	4-10
4-7	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Cadmium	4-11
4-8	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Methylmercury (IRIS RfD)	4-12
4-9	Monthly Consumption Limits for Developmental Health Endpoints for Women of Reproductive Age—Methylmercury (IRIS RfD)	4-13
4-10	Monthly Consumption Limits for Developmental Health Endpoints for Children—Methylmercury (IRIS RfD)	4-14
4-11	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Selenium	4-15
4-12	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Selenium	4-16
4-13	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Tributyltin Oxide	4-17
4-14	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Tributyltin Oxide	4-18
4-15	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Chlordane	4-19
4-16	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Chlordane	4-20
4-17	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Chlordane	4-21
4-18	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—DDT	4-22
4-19	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—DDT	4-23
4-20	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—DDT	4-24
4-21	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Dicofol	4-25
4-22	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Dicofol	4-26
4-23	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Dicofol	4-27

LIST OF TABLES

Number		Page
4-24	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Dieldrin	4-28
4-25	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Dieldrin	4-29
4-26	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Dieldrin	4-30
4-27	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Endosulfan	4-31
4-28	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Endosulfan	4-32
4-29	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Endrin	4-33
4-30	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Endrin	4-34
4-31	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Heptachlor Epoxide	4-35
4-32	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Heptachlor Epoxide	4-36
4-33	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Heptachlor Epoxide	4-37
4-34	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Hexachlorobenzene	4-38
4-35	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Hexachlorobenzene	4-39
4-36	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Hexachlorobenzene	4-40
4-37	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Lindane	4-41
4-38	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Lindane	4-42
4-39	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Lindane	4-43
4-40	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Mirex	4-44
4-41	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Mirex	4-45
4-42	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Mirex	4-46
4-43	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Toxaphene (OW/OPP RfD)	4-47
4-44	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Toxaphene (OW/OPP RfD)	4-48
4-45	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Toxaphene	4-49
4-46	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Chlorpyrifos	4-50

LIST OF TABLES

Number		Page
4-47	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Chlorpyrifos	4-51
4-48	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Diazinon	4-52
4-49	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Diazinon	4-53
4-50	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Disulfoton	4-54
4-51	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Disulfoton	4-55
4-52	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Ethion	4-56
4-53	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Ethion	4-57
4-54	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Terbufos	4-58
4-55	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Terbufos	4-59
4-56	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—Oxyfluorfen	4-60
4-57	Monthly Consumption Limits for Chronic Systemic Health Endpoints for Children—Oxyfluorfen	4-61
4-58	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Oxyfluorfen	4-62
4-59	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—PAHs	4-63
4-60	Monthly Consumption Limits for Chronic Systemic Health Endpoints for the General Population—PCBs (Arochlor 1254)	4-64
4-61	Monthly Consumption Limits for Developmental Health Endpoints for Women of Reproductive Age—PCBs (Arochlor 1254)	4-65
4-62	Monthly Consumption Limits for Developmental Health Endpoints for Children—PCBs (Arochlor 1254)	4-66
4-63	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—PCBs (Total)	4-67
4-64	Monthly Consumption Limits for Carcinogenic Health Endpoints for the General Population—Dioxins/Furans	4-68
5-1	Health and Toxicological Data Reviewed for Target Analytes	5-3
5-2	Toxicity Equivalent Factors for Various PAHs	5-102
5-3	Relative Potency Estimates for Various PAHs	5-103
6-1	Comparison of Raster- Versus Vector-Based GIS Programs	6-4